17 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 17 of 17 clinical reviews.
Is it safe to take Praluent (alirocumab) with acetaminophen? A clinical review of pharmacokinetic and pharmacodynamic data, hepatic considerations, monitoring recommendations, and dose guidance.
Is it safe to take Praluent (alirocumab) with apixaban (Eliquis)? A review of what is established, what is plausible, and what still needs verification about this combination.
A careful look at combining alirocumab (Praluent) with atorvastatin: what the FDA label says about pharmacokinetics, what trial evidence shows and does not show, dosing and monitoring considerations, and what still needs verification.
Evidence-based review of whether alirocumab (Praluent) interacts with proton pump inhibitors like omeprazole and pantoprazole, including the pharmacologic reasoning, what the FDA label supports, and what remains unverified.
Clinical analysis of taking Praluent (alirocumab) with SNRIs like venlafaxine or duloxetine. Covers pharmacokinetic pathways, safety data, monitoring, and physician guidance.
Clinical guide to combining alirocumab (Praluent) with testosterone replacement therapy. Covers mechanism, severity, lipid monitoring, dose adjustment, and patient counseling.
A guide to the alirocumab (Praluent) and clopidogrel drug interaction, covering mechanism, safety evidence, monitoring, and patient counseling.
Board-reviewed analysis of the alirocumab (Praluent) and gabapentin drug interaction, covering CYP450 pathways, renal clearance, pharmacodynamic overlap, and monitoring guidance.
A clinical review of the alirocumab (Praluent) and levothyroxine drug interaction: mechanism, evidence status, monitoring parameters, and patient counseling points, with claims separated by evidence level.
Is it safe to take Praluent (alirocumab) with metformin? A clinical review of drug interaction data, pharmacokinetics, monitoring recommendations, and real-world evidence for this common combination.
A clinical deep-dive into the alirocumab (Praluent) and NSAID interaction, covering pharmacokinetic and pharmacodynamic mechanisms, renal and GI risk, monitoring strategies, and patient counseling guidance.
A detailed clinical review of the alirocumab (Praluent) and pregabalin drug interaction, covering mechanism, pharmacokinetics, severity classification, monitoring recommendations, and patient counseling guidance.
A guide to the alirocumab (Praluent) and rivaroxaban drug interaction: mechanism, safety evidence, monitoring parameters, and patient counseling points.
Can you take Praluent (alirocumab) with rosuvastatin? A cautious review of what is established, what is pharmacologically plausible, and what still needs clinician verification for this common PCSK9 inhibitor-statin combination.
A guide to the alirocumab and SSRI interaction, covering mechanism, safety data, monitoring, and patient counseling for sertraline and escitalopram coadministration.
Alirocumab (Praluent) and tadalafil (Cialis) have no known pharmacokinetic interaction. Learn about their separate metabolic pathways, cardiovascular overlap, monitoring recommendations, and clinical evidence.
Can you take Praluent (alirocumab) with warfarin? A review of the pharmacologic basis for this combination, what trial evidence does and does not show, and a practical monitoring approach.